ERNA
ERNA
NASDAQ · Biotechnology

Ernexa Therapeutics Inc

$0.20
+0.01 (+7.57%)
As of Mar 31, 5:05 PM ET ·
Financial Highlights (FY 2026)
Revenue
18.68M
Net Income
-1,429,349,563
Gross Margin
83.5%
Profit Margin
-7,652.8%
Rev Growth
-69.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.5% 83.5% 35.7% 35.7%
Operating Margin -6,548.8% -5,893.9% -3.8% -3.6%
Profit Margin -7,652.8% -7,270.1% -3.2% -3.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 18.68M 60.52M 759.7K 723.6K
Gross Profit 15.60M 50.54M 270.9K 258.0K
Operating Income -1,223,156,769 -3,567,210,279 -28,606 -26,110
Net Income -1,429,349,563 -4,168,550,248 -24,634 -22,962
Gross Margin 83.5% 83.5% 35.7% 35.7%
Operating Margin -6,548.8% -5,893.9% -3.8% -3.6%
Profit Margin -7,652.8% -7,270.1% -3.2% -3.2%
Rev Growth -69.1% -69.1% +6.1% +6.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.20M 1.05M
Total Equity 1.80M 2.01M
D/E Ratio 0.67 0.52
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -1,201,046,396 -3,697,323,642 -38,889 -37,851
Free Cash Flow -29,815 -29,431